Community acquired pneumonia in the tropics

Current Opinion in Pulmonary Medicine

Volumn 13, Issue 3, 2007, Pages 170-176

  Scrimini, Sergio ^a   Junemann, Andrea ^a   Luna, Carlos M ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b NONE   (Argentina)

Author keywords

Community acquired pneumonia; Respiratory infections; Tropical diseases

Indexed keywords

AMANTADINE; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZITHROMYCIN; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; DOXYCYCLINE; GATIFLOXACIN; INFLUENZA VACCINE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OSELTAMIVIR; QUINOLONE DERIVATIVE; RIBAVIRIN; RIMANTADINE; ZANAMIVIR;

ACINETOBACTER BAUMANNII; ANTIBIOTIC THERAPY; AVIAN INFLUENZA; COMMUNITY ACQUIRED PNEUMONIA; EXPOSURE; GEOGRAPHIC DISTRIBUTION; HANTAVIRUS; HANTAVIRUS PULMONARY SYNDROME; HUMAN; INCUBATION TIME; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A H5N1; LEGIONELLA; LEGIONNAIRE DISEASE; MELIOIDOSIS; MICROORGANISM; MIGRATION; PATHOGENESIS; PHYSICAL EXAMINATION; PREVALENCE; Q FEVER; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY VIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SERODIAGNOSIS; SEVERE ACUTE RESPIRATORY SYNDROME; TRAVEL; TROPICS; VIRUS CULTURE;

COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA; PREVALENCE; RISK FACTORS; WORLD HEALTH;

EID: 34247149376     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3280ebb5dc     Document Type: Review

References (77)

1. Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006; 354:119-130. Travel destinations are associated with the probability of the diagnosis of certain diseases. Diagnostic approaches and empiric therapies can be guided by these destination-specific differences.
2. Chew FT, Doraisingham S, Ling AE, et al. Seasonal trends of viral respiratory tract infections in the tropics. Epidemiol Infect 1998; 121:121-128.
3. Shek LP, Lee BW. Epidemiology and seasonality of respiratory tract virus infections in the tropics. Paediatr Respir Rev 2003; 4:105-111.
4. Zuckerman JN. Imported tropical respiratory tract infections. Curr Opin Pulm Med 1999; 5:164-167.
5. Lassalle C, Grizeau P, Isautier H, et al. Epidemiological surveillance of grippe and dengue. Reunion 1996. Bull Soc Pathol Exot 1998; 91:61-63.
6. Linde A. The importance of specific virus diagnosis and monitoring for antiviral treatment. Antiviral Res 2001; 51:81-94.
7. Hall CB. Nosocomial respiratory syncytial virus infections: the 'Cold War' has not ended. Clin Infect Dis 2000; 31:590-596.
8. Greenberg SB. Respiratory viral infections in adults. Curr Opin Pulm Med 2002; 8:201-208.
9. Munoz FM, Galasso GJ, Gwaltney JM Jr, et al. Current research on influenza and other respiratory viruses: II international symposium. Antiviral Res 2000; 46:91-124.
10. Dominguez KD, Mercier RC. Treatment of RSV pneumonia in adults: evidence of ribavirin effectiveness? Ann Pharmacother 1999; 33:739-741.
11. Lamb RA, Krug RM. Orthoviridae, the virus and their replication. In: Fields BN, Howley PM, editors. Fields virology. Philadelphia: Lippincott Raven; 1996. pp. 1353-1445.
12. Wong SS, Yuen KY. Avian influenza virus infections in humans. Chest 2006; 129:156-158. The epidemiology, virology, clinical features, laboratory diagnosis, management, and hospital infection control measures for avian influenza are reviewed from a clinical perspective.
13. Cunha BA. Influenza: historical aspects of epidemics and pandemics. Infect Dis Clin North Am 2004; 18:141-155.
14. Fedson DS. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Public Health Policy 2005; 26:4-29.
15. Yuen K, Chan P, Peiris M, et al. Clinical features and rapid diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998; 351:467-471.
16. World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. 2006, Epidemic and Pandemic Alert and Response (EPR). Geneva: WHO; 2006.
17. Kaye D, Pringle CR. Avian influenza viruses and their implications for human health. Clin Inf Dis 2005; 40:108-112.
18. Poland GA. Vaccine against avian influenza: a race against time. N Engl J Med 2006; 354:1411-1413. This is an editorial about how new pandemics should be faced with multiple, parallel avenues of vaccine development.
19. Stiver G. The treatment of influenza with antiviral drugs. CMAJ 2003; 148:49-56.
20. The macroepidemiology of influenza vaccine (MIV) study group. The macroepidemiology of influenza vaccine in 45 countries. Vaccine 2005; 23: 533-543.
21. Leneva IA, Roberts N, Govorkova EA, et al. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/ 97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 2000; 48:101-115.
22. Raoult D, Marrie T. Q fever. Clin Infect Dis 1995; 20:489-495.
23. Stein A, Saunders NA, Taylor AG, et al. Phylogenic homogeneity of Coxiella burnetii strains as determinated by 16S ribosomal RNA sequencing. FEMS Microbiol Lett 1993; 113:339-344.
24. Stein A, Raoult D, Marrie T. Pigeon pneumonia in provence: a bird-borne Q fever outbreak. Clin Infect Dis 1999; 29:617-620.
25. Dupuis G, Petite J, Peter O, Vouilloz M. An important outbreak of human Q fever in a Swiss Alpine valley. Int J Epidemiol 1987; 16:282-287.
26. Raoult D, Tissot-Dupont H, Foucault C, et al. Q fever 1985-1998. Clinical and epidemiologic features of 1,383 infections. Medicine (Baltimore) 2000; 79:109-123.
27. Marrie TJ. Coxiella burnetti pneumonia. Eur Respir J 2003; 21:713-719.
28. Fournier PE, Marrie TJ, Raoult D, Marrie T. Diagnosis of Q fever. J Clin Microbiol 1998; 36:1823-1834.
29. Fenollar F, Fournier PE, Carrieri MP, et al. Risks factors and prevention of Q fever endocarditis. Clin Infect Dis 2001; 33:312-316.
30. Boulos A, Rolain JM, Maurin M, et al. Measurement of the antibiotic susceptibility of Coxiella burnetii using real time PCR. Int J Antimicrob Agents 2004; 23:169-174.
31. Gikas A, Kofteridis DP, Manios A, et al. Newer macrolides as empiric treatment for acute Q fever infection. Antimicrob Agents Chemother 2001; 45:3644-3646.
32. Chen MZ, Hsueh PR, Lee LN, et al. Severe community-acquired pneumonia due to Acinetobacter baumannii. Chest 2001; 120:1072-1077.
33. Rosenthal SL. Sources of Pseudomonas and Acinetobacter species found in human culture material. Am J Clin Pathol 1974; 62:807-811.
34. Anstey NM, Currie BJ, Withnall KM. Community-acquired Acinetobacter pneumonia in the northern territory of Australia. Clin Infect Dis 1992; 14:83-91.
35. Leung WS, Chu CM, Tsang KY, et al. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. Chest 2006; 129:102-109. This describes a retrospective case-control study comparing CAP-Acinetobacter baumannii (AB) and HAP-AB patients, performed at an Australian hospital between 2000 and 2003.
36. Zaki SR, Khan AS, Goodman RA, et al. Retrospective diagnosis of hantavirus pulmonary syndrome, 1978-1993: implications for emerging infectious diseases. Arch Pathol Lab Med 1996; 120:134-139.
37. Wilson C, Hjelle B, Jenison S. Probable hantavirus pulmonary syndrome that occurred in New Mexico in 1975. Ann Intern Med 1994; 120:813-817.
38. Weissenbacher MC, Cura E, Segura EL, et al. Serological evidence of human hantavirus infection in Argentina, Bolivia and Uruguay. Medicina (B Aires) 1996; 56:17-22.
39. Padula PJ, Colavecchia SB, Martinez VP, et al. Hantavirus-pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. Virology 1998; 241:323-330.
40. Lee HW, van der Groen G. Hemorrhagic fever with renal syndrome. Prog Med Virol 1989; 36:62-102.
41. Duchin JS, Koster FT, Peters CJ, et al. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The Hantavirus Study Group. N Engl J Med 1994; 330:949-955.
42. Passaro DJ, Shieh WJ, Hacker JK, et al. Predominant kidney involvement in a fatal case of hantavirus pulmonary syndrome caused by Sin Nombre virus. Clin Infect Dis 2001; 33:263-264.
43. Ketai LH, Williamson MR, Telepak RJ. Hantavirus pulmonary syndrome: radiographic findings in 16 patients. Radiology 1994; 191:665-668.
44. Jenison S, Yamada T, Morris C, et al. Characterization of human antibody responses to four corners hantavirus infections among patients with hantavirus pulmonary syndrome. J Virol 1994; 68:3000-3006.
45. Hjelle B, Spiropoulou CF, Torrez-Martinez N, et al. Detection of Muerto Canyon virus RNA in peripheral blood mononuclear cells from patients with hantavirus pulmonary syndrome. J Infect Dis 1994; 170:1013-1017.
46. Levy H. Hantavirus infection. In: Niederman MS, Sarosi G, Glassroth J, editors. Respiratory infections. Philadelphia: Lippincott Williams and Wilkins; 2001. pp. 445-455.
47. Chapman LE, Mertz GJ, Peters CJ, et al. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther 1999; 4:211-219.
48. Benson RF, Thacker WL, Fang FC, et al. Legionella sainthelensi serogroup 2 isolated from patients with pneumonia. Res Microbiol 1990; 141:453-463.
49. Pachon J, Prados MD, Capote F, et al. Severe community-acquired pneumonia. Etiology, prognosis, and treatment. Am Rev Respir Dis 1990; 142:369-373.
50. Lieberman D, Porath A, Schlaeffer F, et al. Legionella species community-acquired pneumonia. A review of 56 hospitalized adult patients. Chest 1996; 109:1243-1249.
51. Marrie TJ, Peeling RW, Fine MJ, et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996; 101:508-515.
52. Kirby BD, Snyder KM, Meyer RD, Finegold SM. Legionnaires' disease: report of sixty-five nosocomially acquired cases of review of the literature. Medicine (Baltimore) 1980; 59:188-205.
53. Helms CM, Massanari RM, Zeitler R, et al. Legionnaires' disease associated with a hospital water system: a cluster of 24 nosocomial cases. Ann Intern Med 1983; 99:172-178.
54. Haley CE, Cohen ML, Halter J, Meyer RD. Nosocomial Legionnaires' disease: a continuing common-source epidemic at Wadsworth Medical Center. Ann Intern Med 1979; 90:583-586.
55. Marks JS, Tsai TF, Martone WJ, et al. Nosocomial Legionnaires' disease in Columbus, Ohio. Ann Intern Med 1979; 90:565-569.
56. Mulazimoglu L, Yu VL. Can Legionnaires disease be diagnosed by clinical criteria? A critical review. Chest 2001; 120:1049.
57. Tan MJ, Tan JS, Hamor RH, et al. The radiologic manifestations of Legionnaire's disease. The Ohio Community-Based Pneumonia Incidence Study Group. Chest 2000; 117:398-403.
58. Dance DA. Ecology of Burkholderia pseudomallei and the interactions between environmental Burkholderia spp. and human-animal hosts. Acta Trop 2000; 74:159-168.
59. Leelarasamee A, Bovornkitti S. Melioidosis: review and update. Rev Infect Dis 1989; 11:413-425.
60. Currie BJ, Fisher DA, Howard DM, et al. The epidemiology of melioidosis in Australia and Papua New Guinea. Acta Trop 2000; 74:121-127.
61. Currie BJ, Jacups SP. Intensity of rainfall and severity of melioidosis, Australia. Emerg Infect Dis 2003; 9:1538-1542.
62. Kanaphun P, Thirawattanasuk N, Suputtamongkol Y, et al. Serology and carriage of Pseudomonas pseudomallei: a prospective study in 1000 hospitalized children in northeast Thailand. J Infect Dis 1993; 167:230-233.
63. Currie BJ, Fisher DA, Anstey NM, Jacups SP. Melioidosis: acute and chronic disease, relapse and re-activation. Trans R Soc Trop Med Hyg 2000; 94:301-304.
64. Chaowagul W, White NJ, Dance DA, et al. Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis 1989; 159:890-899.
65. Christian MD, Poutanen SM, Loutfy MR, et al. Severe acute respiratory syndrome. Clin Infect Dis 2004; 38:1420-1427.
66. Luna CM, Faure C. Common tropical pneumonias, diagnosis and therapy. In: Sharma OP, editor. Tropical lung diseases. New York: Taylor & Francis Group; 2006. pp. 117-142. This is a review of the diagnosis and therapy of common pneumonias in the tropics in different world areas.
67. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348:1977-1985.
68. Donnelly CA, Fisher MC, Fraser C, et al. Epidemiological and genetic analysis of severe acute respiratory syndrome. Lancet Infect Dis 2004; 4:672-683.
69. Donnelly CA, Ghani AC, Leung GM, et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003; 361:1761-1766.
70. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003; 348:1995-2005.
71. Nicolaou S, Al-Nakshabandi NA, Muller NL. SARS: imaging of severe acute respiratory syndrome. AJR Am J Roentgenol 2003; 180:1247-1249.
72. Bitar R, Weiser WJ, Avendano M, et al. Chest radiographic manifestations of severe acute respiratory syndrome in healthcare workers: the Toronto experience. AJR Am J Roentgenol 2004; 182:45-48.
73. Muller NL, Ooi GC, Khong PL, Nicolaou S. Severe acute respiratory syndrome: radiographic and CT findings. AJR Am J Roentgenol 2003; 181:3-8.
74. Muller MP, Richardson SE, McGeer A, et al. Early diagnosis of SARS: lessons from the Toronto SARS outbreak. Eur J Clin Microbiol Infect Dis 2006; 25:230-237. The clinical presentation of SARS is nonspecific and diagnostic tests do not provide accurate results early in the disease course. Initial diagnosis remains reliant on clinical assessment.
75. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59:252-256.
76. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003; 289:2801-2809.
77. Ho JC, Ooi GC, Mok TY, et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 2003; 168:1449-1456.